Subscribe
shutterstock_1803358558_rafapress
rafapress / Shutterstock.com
10 December 2020AmericasRory O'Neill

Tris blocks Actavis’ ADHD generic

New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder (ADHD) drug Quillivant XR (methylphenidate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More on this story

Americas
Federal Circuit rejects ADHD generic drug challenge
8 July 2022   A major generic pharma company has failed to undo patents related to the oral suspension Quillivant XR.
Americas
Number of pay-for-delay deals remains low, says FTC
7 December 2020   The number of potentially anticompetitive patent infringement settlements between brand drugmakers and generic competitors remained low in 2017, according to the Federal Trade Commission.
Americas
Judge gives initial approval to Actavis $20m antitrust deal
15 September 2020   A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

More features

AbbVie blocks Humira antitrust suit
WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory